What is Rivia?
Rivia is a Switzerland-based healthtech company that has developed an AI-powered platform designed to unify and analyze clinical trial data. Its technology empowers biotech and pharmaceutical teams by streamlining operations, enhancing data quality, and facilitating faster, more informed decision-making. The platform's ability to process complex datasets positions Rivia as a key player in accelerating drug discovery and development pipelines.
How much funding has Rivia raised?
Rivia has raised a total of $18.8M across 2 funding rounds:
Seed
$3.5M
Series A
$15.2M
Seed (2024): $3.5M with participation from Speedinvest
Series A (2026): $15.2M led by Earlybird, Speedinvest, Amino Collective, and Nina Capital
Key Investors in Rivia
Speedinvest
Speedinvest is a venture capital fund focused on early-stage tech startups across Europe, providing capital and hands-on support in sectors including Health Bio and Deep Tech.
Earlybird
Earlybird is a venture capital investor with a focus on European technology innovators, investing in sectors such as technology and medical.
Amino Collective
Amino Collective invests in the health and bio sectors, supporting early-stage European ventures with a focus on scaling globally and backing innovative founders.
What's next for Rivia?
With substantial backing and a clear strategic direction, Rivia is poised for accelerated growth and market expansion. The recent major strategic investment signals confidence from its investors in Rivia's capacity to scale its AI platform and deepen its impact within the healthtech ecosystem. Future developments are likely to focus on enhancing platform capabilities, forging new partnerships, and further solidifying its position as a leader in clinical trial data intelligence, driving innovation in healthcare.
See full Rivia company page
